SUMMIT - Une étude « panier » marque des points

Armelle Luscan; Éric Pasmant

doi:10.1051/medsci/2018232

Accueil

Tous les numéros

Volume 34 / Numéro 11 (Novembre 2018)

Med Sci (Paris), 34 11 (2018) 910-913

Références

Open Access

Numéro		Med Sci (Paris) Volume 34, Numéro 11, Novembre 2018


Page(s)		910 - 913
Section		Le Magazine
DOI		https://doi.org/10.1051/medsci/2018232
Publié en ligne		10 décembre 2018

Ding L, Bailey MH, Porta-Pardo E, et al. Perspective on oncogenic processes at the end of the beginning of cancer genomics. Cell 2018 ; 173 : 305–320. [CrossRef] [PubMed] [Google Scholar]
Mishra R, Hanker AB, Garrett JT. Genomic alterations of ERBB receptors in cancer: clinical implications. Oncotarget 2017 ; 8 : 114371–114392. [PubMed] [Google Scholar]
Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007 ; 369 : 29–36. [CrossRef] [PubMed] [Google Scholar]
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010 ; 376 : 687–697. [CrossRef] [PubMed] [Google Scholar]
Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005 ; 5 : 341–354. [Google Scholar]
Larbouret C, Gaborit N, Poul MA, et al. Le récepteur HER3 ou ERB3 - La face cachée de la planète ERB. Med Sci (Paris) 2015 ; 31 : 465–468. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 2018 ; 554 : 189–194. [CrossRef] [PubMed] [Google Scholar]
Mainardi S, Mulero-Sánchez A, Prahallad A, et al. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. Nat Med 2018 ; 7 : 961–967. [Google Scholar]
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001 ; 344 : 783–792. [CrossRef] [PubMed] [Google Scholar]
Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015 ; 372 : 724–734. [CrossRef] [PubMed] [Google Scholar]
Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012 ; 379 : 633–640. [CrossRef] [PubMed] [Google Scholar]
Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 2016 ; 17 : 738–746. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.

[1] Ding L, Bailey MH, Porta-Pardo E, et al. Perspective on oncogenic processes at the end of the beginning of cancer genomics. Cell 2018 ; 173 : 305–320. [CrossRef] [PubMed] [Google Scholar]

[2] Mishra R, Hanker AB, Garrett JT. Genomic alterations of ERBB receptors in cancer: clinical implications. Oncotarget 2017 ; 8 : 114371–114392. [PubMed] [Google Scholar]

[3] Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007 ; 369 : 29–36. [CrossRef] [PubMed] [Google Scholar]

[4] Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010 ; 376 : 687–697. [CrossRef] [PubMed] [Google Scholar]

[5] Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005 ; 5 : 341–354. [Google Scholar]

[6] Larbouret C, Gaborit N, Poul MA, et al. Le récepteur HER3 ou ERB3 - La face cachée de la planète ERB. Med Sci (Paris) 2015 ; 31 : 465–468. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

[7] Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 2018 ; 554 : 189–194. [CrossRef] [PubMed] [Google Scholar]

[8] Mainardi S, Mulero-Sánchez A, Prahallad A, et al. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. Nat Med 2018 ; 7 : 961–967. [Google Scholar]

[9] Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001 ; 344 : 783–792. [CrossRef] [PubMed] [Google Scholar]

[10] Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015 ; 372 : 724–734. [CrossRef] [PubMed] [Google Scholar]

[11] Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012 ; 379 : 633–640. [CrossRef] [PubMed] [Google Scholar]

[12] Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 2016 ; 17 : 738–746. [CrossRef] [PubMed] [Google Scholar]